Pharmacologic Drug Detection and Self-Reported Adherence in the HPTN069/ACTG5305 Phase II PrEP Trial

By sjmartinez • August 1, 2024

Cooper SE, Zhang S, Haines D, Mayer KH, Amico KR, Landovitz RJ, Hendrix CW, Marzinke MA, Chege W, McCauley M, Gulick RM. Pharmacologic Drug Detection and Self-Reported Adherence in the HPTN069/ACTG5305 Phase II PrEP Trial. AIDS Behav. 2024 Jul 31. doi: 10.1007/s10461-024-04451-7. Epub ahead of print. PMID: 39083151.

Tags: Adherence, CASI, HIV prevention, Infectious Diseases, Maraviroc, PrEP, Publications, Tenofovir

Related Posts

Integration of HIV pre-exposure prophylaxis (PrEP) services for pregnant and breastfeeding women in eight primary care clinics: results of an implementation science study

Nelson A, Bheemraj K, Dean SS, de Voux A, Hlatshwayo L, Mvududu R, Berkowitz N, Neumuller C, Jacobs S, Fourie S, Coates T, Gail-Bekker L,[...]

How I Do It: Managing Cavitary Coccidioidomycosis Expert Opinions for Improving Patient Outcomes

Donovan FM, Thompson GR 3rd, Blair JE, Johnson RH, Malo J, Albasha W, Worrell SG, Beamer SE, Yaddanapudi K, Galgiani JN, Ampel NM. How I[...]

Safety, tolerability, pharmacokinetics, and neutralisation activities of the anti-HIV-1 monoclonal antibody PGT121.414.LS administered alone and in combination with VRC07-523LS in adults without HIV in the USA (HVTN 136/HPTN 092): a first-in-human, open-label, randomised controlled phase 1 trial

Edupuganti S, Hurt CB, Stephenson KE, Huang Y, Paez CA, Yu C, Yen C, Hanscom B, He Z, Miner MD, Gamble T, Heptinstall J, Seaton[...]